Evolent Health Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: September-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
Evolent has dispersed ownership, but founder leadership concentrates operating knowledge and makes succession planning a material governance issue. We see this as the central issue in control and governance because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.Public shareholders own Evolent Health, while co-founder Seth Blackley leads the company under independent chair Frank Williams. Seth Blackley leads the enterprise and Frank Williams provides board or owner oversight, so formal percentages must be read beside board independence, voting rights and contractual authority. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: medical-cost forecasting, customer concentration, contract transitions, claims volatility, leverage, impairments, regulation and integration can consume liquidity. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At a September 2026 equity value of $476.05 million, the market discounts high execution risk despite substantial contracted revenue growth. A premium is earned only when measurable cash economics, resilient governance and disciplined reinvestment persist through a full cycle. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would tie executive rewards to per-share value, balance-sheet resilience and clearly measured strategic outcomes. We would prioritize cash conversion, contract-level reserve transparency and debt reduction before pursuing another large acquisition. Our view is that Evolent Health deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes instead of corporate activity.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Institutional owners can demand better disclosure, yet contract reserves and medical-cost assumptions require deeper scrutiny than index ownership provides. We see this as the central issue in shareholder composition and capital-market behavior because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The ownership register lists The Vanguard Group, BlackRock, T. Rowe Price, FMR at 10.9%, 9.5%, 7.1%, 6.3%. These stakes influence elections, liquidity and engagement, but they do not guarantee a common view on strategy or risk. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: medical-cost forecasting, customer concentration, contract transitions, claims volatility, leverage, impairments, regulation and integration can consume liquidity. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At a September 2026 equity value of $476.05 million, the market discounts high execution risk despite substantial contracted revenue growth. A premium is earned only when measurable cash economics, resilient governance and disciplined reinvestment persist through a full cycle. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We expect major holders to press for transparent capital priorities, credible downside planning and disciplined compensation. We would prioritize cash conversion, contract-level reserve transparency and debt reduction before pursuing another large acquisition. Our view is that Evolent Health deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes instead of corporate activity.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| Evolent Health | Corporate brand | Specialty care management |
| Evolent Specialty Services | Operating platform | Oncology cardiology and musculoskeletal care |
| New Century Health | Subsidiary brand | Oncology and cardiology management |
| Machinify | Technology platform | Artificial intelligence claims intelligence |
| Vital Decisions | Subsidiary brand | Advance care planning |
| Interventional Pain and Spine Group | Subsidiary platform | Musculoskeletal procedure management |
Portfolio Analysis
The brands combine clinical pathways, specialty networks and claims technology, and their value depends on measurable medical-cost improvement. We see this as the central issue in brand and portfolio strategy because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The portfolio includes Evolent Health, Evolent Specialty Services, New Century Health, Machinify, Vital Decisions and Interventional Pain and Spine Group. Each identity needs a defined customer promise and economic role, with shared capabilities producing measurable benefits instead of administrative complexity. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: medical-cost forecasting, customer concentration, contract transitions, claims volatility, leverage, impairments, regulation and integration can consume liquidity. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At a September 2026 equity value of $476.05 million, the market discounts high execution risk despite substantial contracted revenue growth. A premium is earned only when measurable cash economics, resilient governance and disciplined reinvestment persist through a full cycle. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would invest behind identities with the strongest incremental returns and simplify offerings that do not reinforce customer advantage. We would prioritize cash conversion, contract-level reserve transparency and debt reduction before pursuing another large acquisition. Our view is that Evolent Health deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes instead of corporate activity.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| Evolent Health ★ | N/A | $1.88B FY2025 | Specialty care management platform |
| Carelon | Elevance Health | N/A | Health benefits and specialty services |
| Optum | UnitedHealth Group | N/A | Healthcare services and analytics |
| The Cigna Group | N/A | $247B FY2025 | Care management and pharmacy services |
| Progyny | N/A | $1B FY2025 | Specialty benefits management |
Competitive Analysis
Specialty focus creates expertise, while diversified insurers and services platforms can bundle competing capabilities with broader distribution. We see this as the central issue in competitive position and valuation because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The current performance base is 2025 revenue of $1.876 billion and a $579.4 million net loss, followed by strong 2026 revenue growth from new Performance Suite contracts. We test competitive strength through pricing, retention, market share, unit economics and return on invested capital instead of broad claims about addressable markets. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: medical-cost forecasting, customer concentration, contract transitions, claims volatility, leverage, impairments, regulation and integration can consume liquidity. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At a September 2026 equity value of $476.05 million, the market discounts high execution risk despite substantial contracted revenue growth. A premium is earned only when measurable cash economics, resilient governance and disciplined reinvestment persist through a full cycle. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would track leading indicators of pricing power and retention before assuming any cyclical improvement is permanent. We would prioritize cash conversion, contract-level reserve transparency and debt reduction before pursuing another large acquisition. Our view is that Evolent Health deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes instead of corporate activity.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| Machinify | $750M | 2024 | Added artificial intelligence claims intelligence |
| Interventional Pain and Spine Group | $375M | 2022 | Expanded musculoskeletal specialty management |
| Vital Decisions | $85M | 2021 | Added advance care planning |
| New Century Health | $217M | 2018 | Established oncology and cardiology management scale |
Acquisitions Analysis
Machinify adds differentiated technology, but the purchase increased leverage and arrived before prior acquisitions had fully proved durable returns. We see this as the central issue in acquisition discipline and integration because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The transaction record matters because management is integrating Machinify, reducing operating cost and funding contract growth while managing debt and working-capital demands. We expect post-deal scorecards to compare promised economics with retention, margins, cash conversion and financing costs. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: medical-cost forecasting, customer concentration, contract transitions, claims volatility, leverage, impairments, regulation and integration can consume liquidity. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At a September 2026 equity value of $476.05 million, the market discounts high execution risk despite substantial contracted revenue growth. A premium is earned only when measurable cash economics, resilient governance and disciplined reinvestment persist through a full cycle. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would require a conservative base case, an explicit failure case and a formal post-close review before approving another material transaction. We would prioritize cash conversion, contract-level reserve transparency and debt reduction before pursuing another large acquisition. Our view is that Evolent Health deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes instead of corporate activity.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Acquisitions and divestitures narrowed Evolent toward specialty care, but restructuring charges reveal the cost of strategic repositioning. We see this as the central issue in merger, spinoff and structural history because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.Evolent was formed as an independent value-based care company with backing from health-system partners and private investors. Its public offering funded expansion, while New Century Health, Vital Decisions, Interventional Pain and Spine Group and Machinify progressively concentrated the company on specialty care. Portfolio exits and restructuring reduced peripheral administrative services but produced impairment and execution costs. Today's segments, leverage, ownership rights and strategic choices are direct consequences of those structural decisions. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: medical-cost forecasting, customer concentration, contract transitions, claims volatility, leverage, impairments, regulation and integration can consume liquidity. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At a September 2026 equity value of $476.05 million, the market discounts high execution risk despite substantial contracted revenue growth. A premium is earned only when measurable cash economics, resilient governance and disciplined reinvestment persist through a full cycle. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would support another structural move only if quantified benefits exceed integration cost, leverage and lost flexibility. We would prioritize cash conversion, contract-level reserve transparency and debt reduction before pursuing another large acquisition. Our view is that Evolent Health deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes instead of corporate activity.
Ownership History
Ownership History Analysis
The company evolved from broad population health enablement to specialty risk management, making underwriting discipline central to owner value. We see this as the central issue in ownership and strategic evolution because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The defining arc is a founder-led value-based care company that used acquisitions to become a focused specialty management platform. We assign heritage value only when its best operating lessons remain embedded in incentives, succession and capital discipline. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: medical-cost forecasting, customer concentration, contract transitions, claims volatility, leverage, impairments, regulation and integration can consume liquidity. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At a September 2026 equity value of $476.05 million, the market discounts high execution risk despite substantial contracted revenue growth. A premium is earned only when measurable cash economics, resilient governance and disciplined reinvestment persist through a full cycle. Investors should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would preserve capabilities that created the franchise while discarding legacy practices that no longer earn adequate returns. We would prioritize cash conversion, contract-level reserve transparency and debt reduction before pursuing another large acquisition. Our view is that Evolent Health deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes instead of corporate activity.
Ownership Explained
Evolent Health operates under this ownership structure: Public shareholders own Evolent Health, while co-founder Seth Blackley leads the company under independent chair Frank Williams. Seth Blackley leads the enterprise and Frank Williams provides board or owner oversight. We treat voting authority, board composition and contractual rights as more informative than a shareholder list alone because they determine who can change strategy, approve transactions and set risk tolerance.The operating model is a specialty care management company that accepts clinical and financial responsibility for oncology, cardiology and musculoskeletal populations. Important commercial identities include Evolent Health, Evolent Specialty Services, New Century Health, Machinify, Vital Decisions and Interventional Pain and Spine Group. We see value when these businesses share technology, distribution, procurement or customer insight without weakening local accountability. Portfolio breadth deserves a premium only when common ownership improves retention, margins and reinvestment returns.The latest annual record includes 2025 revenue of $1.876 billion and a $579.4 million net loss, followed by strong 2026 revenue growth from new Performance Suite contracts. We use the annual period as the clean scale reference and incorporate current 2026 developments when they alter control, governance or earnings power. Interim results can be distorted by seasonality, transaction timing, launch costs, reserve adjustments or volatile end markets.Management is integrating Machinify, reducing operating cost and funding contract growth while managing debt and working-capital demands. Our view is that capital allocation is the practical expression of ownership. Management and directors should compare each acquisition, distribution, repurchase, development program or restructuring decision with debt reduction and retained liquidity, then report whether actual returns matched the original underwriting.
Ownership shapes disclosure, financing flexibility and accountability at Evolent Health. Public shareholders own Evolent Health, while co-founder Seth Blackley leads the company under independent chair Frank Williams. We expect the controlling parties and directors to convert authority into durable per-share value rather than treating revenue growth, asset count or transaction volume as ends in themselves.The principal downside exposures are medical-cost forecasting, customer concentration, contract transitions, claims volatility, leverage, impairments, regulation and integration can consume liquidity. We would monitor leading operating indicators that reveal whether the franchise is strengthening before reported earnings fully show the change. Balance-sheet resilience belongs inside ownership analysis because it preserves strategic choice when demand, regulation or capital markets become less favorable.At a September 2026 equity value of $476.05 million, the market discounts high execution risk despite substantial contracted revenue growth. That benchmark raises the hurdle for new investment and makes scenario discipline essential. We would compare management's implied expectations with conservative cash returns after financing, integration, stock compensation, reserve changes and restructuring costs instead of relying on adjusted profit alone.We would prioritize cash conversion, contract-level reserve transparency and debt reduction before pursuing another large acquisition. This discipline affects investors, employees, customers, suppliers and creditors because it determines service continuity, employment capacity and financial resilience. We see high-quality ownership only when authority produces transparent decisions, measurable accountability and repeatable cash economics.